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Background: Cancer cells frequently adopt cellular and molecular alterations and acquire resistance to cytostatic
drugs. Chemotherapy with oxaliplatin is among the leading treatments for colorectal cancer with a response rate of
50%, inducing intrastrand cross-links on the DNA. Despite of this drug’s efficiency, resistance develops in nearly all
metastatic patients. Chemoresistance being of crucial importance for the drug’s clinical efficiency this study aimed
to contribute to the identification and description of some cellular and molecular alterations induced by prolonged
oxaliplatin therapy. Resistance to oxaliplatin was induced in Colo320 (Colo320R) and HT-29 (HT-29R) colorectal
adenocarcinoma cell lines by exposing the cells to increasing concentrations of the drug. Alterations in
morphology, cytotoxicity, DNA cross-links formation and gene expression profiles were assessed in the parental and
resistant variants with microscopy, MTT, alkaline comet and pangenomic microarray assays, respectively.
Results: Morphology analysis revealed epithelial-to-mesenchymal transition in the resistant vs parental cells
suggesting alterations of the cells’ adhesion complexes, through which they acquire increased invasiveness and
adherence. Cytotoxicity measurements demonstrated resistance to oxaliplatin in both cell lines; Colo320 being
more sensitive than HT-29 to this drug (P < 0.001). The treatment with oxaliplatin caused major DNA cross-links in
both parental cell lines; in Colo320R small amounts of DNA cross-links were still detectable, while in HT-29R not. We
identified 441 differentially expressed genes in Colo320R and 613 in HT-29R as compared to their parental
counterparts (at least 1.5 -fold up- or down- regulation, p < 0.05). More disrupted functions and pathways were
detected in HT-29R cell line than in Colo320R, involving genes responsible for apoptosis inhibition, cellular
proliferation and epithelial-to-mesenchymal transition. Several upstream regulators were detected as activated in
HT-29R cell line, but not in Colo320R.
Conclusions: Our findings revealed a more resistant phenotype in HT-29R as compared to Colo320R and different
cellular and molecular chemoresistance patterns induced by prolonged treatment with oxaliplatin in cell lines with
identical origins (colorectal adenocarcinomas).
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The last decade has brought major improvements in the
treatment of cancers, but in spite of the efficacy of the
cytostatic drugs, in time, cells adopt several cellular and
molecular alterations, acquiring resistance. In colorectal
cancer (CC) the 5 years survival rate remains lower than
10% in patients with metastasis, mainly due to resistance
to the cytostatic drugs [1], regardless of the use of
targeted molecular therapies in addition to standard che-
motherapeutic regimens. The major treatment for meta-
static CC is represented by 5-fluorouracil (5FU) and
oxaliplatin (L-OHP). While 5FU inhibits thymidylate
synthase during DNA replication [2], L-OHP acts as a
bifunctional alkylating agent, covalently binding DNA
and forming platinum-DNA adducts [3]. The intrastrand
cross-links formed by L-OHP being the most abundant
lesions capable of blocking both replication and tran-
scription of DNA, they are considered to cause the
major cytotoxic lesions and being directly involved in
the cancer cells death [4,5].
L-OHP [(1R, 2R)-cyclohexane-1, 2-diamine] (ethane-
dioato-O, O’) platinum (II), a third generation platinum
analogue, is the first compound that have proved to be effi-
cient in the treatment of CC in patients displaying resist-
ance to cisplatin (CDDP) and carboplatin (CBCDA) [6].
Although the response rate to current systemic therapies is
50% resistance develops in almost all patients [7], limiting
the drug’s therapeutic potential. Cells become resistant to
platinum-based drugs through reduced cellular uptake, im-
paired DNA adducts formation, alterations in DNA repair
genes such as ERCC1 and XRCC1 and modifications in the
levels of copper transporters (ATP7A and ATP7B) [8-10].
Although in the last decade the gene expression profil-
ing of human cancer cells provided valuable insight into
the molecular targets of chemoresistance, the mecha-
nisms involved in L-OHP resistance of CC are still
poorly understood and the cellular and molecular alter-
ations are not completely recognized.
Our study proposed to identify and describe some of the
cellular and molecular alterations that occurred in CC cell
lines with induced chemoresistance to L-OHP. In an earl-
ier study, aiming to evaluate the differences in the behav-
ior of the cells selected for L-OHP resistance compared to
the sensitive ones, we assessed the cytotoxicity, apoptosis
and induction of DNA damages by L-OHP in Colo320 CC
cell line. We found lower toxicity, cellular death and fewer
DNA damages, in the cells treated previously with L-OHP
as compared to the parental ones [11]. In the present
study we performed a comparative study on two CC cell
lines (Colo320 and HT-29) with identical origins (adeno-
carcinomas) and their L-OHP resistant counterparts
(Colo320R and HT-29R) obtained by prolonged exposure
to L-OHP. In addition, we analyzed the cells’ morpho-
logical features, DNA cross-links formation and the geneexpression profiles. The DNA cross-links induction by
L-OHP was determined indirectly with alkaline comet
assay (CA), by introducing single strand breaks via ionizing
radiation. The reduction of the single strand-breaks pro-
duced by the ionizing radiation in the cells treated with
L-OHP quantitatively reflected the cross-links induced by
the platinum compound. Gene expression profiling and
subsequent validations with quantitative real-time
PCR (qRT-PCR) were conducted in order to identify
the molecular targets and pathways altered during
chemoresistance acquirement. Finally, a comparative
study was performed between the functions and path-
ways modulated by L-OHP treatment in the tested cell
lines, in order to identify some common patterns of
chemoresistance in CCs.
This study demonstrated that prolonged treatment with
L-OHP induces several cellular and molecular targets and
pathways, which lead to chemoresistance, but these alter-
ations may differ consistently, even if the origins of the
tested cell lines were identical. Results converged to the
conclusion that CC cells change their morphology and
cytotoxicity and react differently to L-OHP therapy by ac-
tivating genes and upstream regulators that resulted in a
more primitive, invasive and migratory, therefore more re-
sistant phenotype. By the identification and description of
the cellular and molecular alterations that occurred during
the chemoresistance acquiring process the present study
aims to contribute to a better understanding of this multi-
factorial process essential in our attempt to reverse




The microscopic analysis revealed distinct morphologic
features for the cells with acquired resistance to L-OHP as
compared to the parental ones. Some of the Colo320R
cells have lost their globular shapes and became fusiforme
and adherent, contrasting to the suspension-type parental
ones. HT-29R cells displayed loss of cell polarity, the
mainly polygonal cells becoming fusiforme, through sev-
eral oblong transitional forms. An increased cell-to-cell
distance between the adherent HT-29R cells was observed
and the presence of pseudopodia in both of the resistant
cell lines (Colo320R and HT-29R) (Figure 1).
Cytotoxicity assessment
The cytotoxicity of L-OHP on the selected CC cell lines
was calculated using a sigmoid-type non-linear regres-
sion method. 2.76 (P < 0.0001) and 2.54 (P < 0.001)-fold
increases of IC50 values were recorded in Colo320R and
HT-29R cell lines, respectively (Table 1). The signifi-
cantly higher IC50 values obtained for the L-OHP-
treated cells vs their parental analogues confirmed the
Figure 1 Microscopic images of Colo320 (a), Colo320R (b), HT-29 (c) and HT-29R (d) CC cell lines. Morphologic analyses revealed round
(a1, c1) and polygonal (c2) types for the sensitive cells. For the resistant ones, transitional (d1) and fusiforme (b2, d2) types of cells were identified
and specific alterations for epithelial-to-mesenchymal transition: presence of pseudopodia (b1; d1), loss of cell polarity and adoption of fusiforme
shape (b2; d2), increased adherence for the generally non-adherent Colo320R (b3) and increased cell-to-cell distance for the HT-29R cells (d4).
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lines. We also found that, at the same dose range,
Colo320 was almost 3-fold more sensitive to L-OHP
than HT-29 cell line (P < 0.001).
Evaluation of the DNA cross-links induced by L-OHP
The lesion scores (LS) calculated in CA revealed that ir-
radiation of the parental cells at a dose of 2 Gy caused
important DNA strand-breaks, Colo320 being more ra-
diosensitive than HT-29 (P < 0.0001 vs. 0.001) (Figure 2),
i.e. more affected by this genotoxic agent.
The exposure of these cells to different concentrations of
L-OHP prior to irradiation reduced significantly the length
of the comet tails, due to the formation of L-OHP-DNA
cross-links. This reduction was significant and dose-
dependent in Colo320 (P < 0.0001), for both concentrations
of the drug; for HT-29 this reduction was less important
(P < 0.001 at 50 μg/ml and P < 0.05 at 100 μg/ml L-OHP)
(Figure 2).
The L-OHP resistant cells displayed different responses
to these treatments, compared to their sensitive counter-
parts. Irradiation with 2 Gy produced insignificant increases
in the LS for both cell lines. Preliminary experimentsTable 1 Cytotoxicity of L-OHP in parental and their L-OHP
resistant variants (Colo320/Colo320R and HT-29/HT-29R)
Cell lines Colo320 Colo320R HT-29 HT-29R
IC50 (μg/ml) 7.546 ± 0.5970 20.85 ± 1.069 22.31 ± 2.717 56.80 ± 5.065
Values are means ± SEM in triplicate, in 3 separate experiments, after 24 h
exposure of the cells to varying concentrations of L-OHP (0.001-300 μg/ml).showed that 50 μg/ml L-OHP did not cause DNA dam-
ages in the resistant variants, neither in the drug-treated
and irradiated nor in the corresponding drug-treated
non-irradiated samples (data not shown). Therefore, we
increased the dose of irradiation (4 Gy) and the concen-
tration of L-OHP (100 μg/ml). 4 Gy caused significant
DNA lesions in HT-29R cell line (P < 0.0001) as com-
pared to control, but these effects were not observable
in Colo320R (Figure 3). The administration of L-OHP
(100 μg/ml) prior to irradiation did not modify notably
the LS in HT-29R, serving as a proof for the acquired
drug-resistance. In Colo320R, the administered L-OHP
(100 μg/ml) still provoked cross-links (P < 0.0001 for
both irradiation doses) (Figure 3).
Gene expression profiles in the tested cells
In order to identify the molecular changes that occurred
during the resistance acquiring process in CC cells, we
performed class comparison analysis of the parental cell
lines (Colo320 and HT-29) and their resistant counter-
parts (Colo320R and HT-29R). Using an M value cut-off
of 0.58 (1.5 fold regulation) and an adjusted p value < 0.05,
we found 441 DE genes in Colo320R vs Colo320,
representing 1.33% of the analyzed genes. Applying the
same criteria of selection, we identified 613 DE genes in
HT-29R vs HT-29 (1.85%). Of the total number of DE
genes modulated by L-OHP in Colo320R, 260 (59%) were
up regulated and 181 (41%) were down regulated. In
HT29R we identified 349 (57%) over expressed and 264
(43%) under expressed genes out of 613. As shown in
Figure 2 Representation of lesion scores (LS) of the Colo320 and Colo320R CC cell lines. Controls (C); irradiated with doses of 2Gy (I/2) and
4Gy (I/4) of gamma irradiations; exposed to 50 μg/ml or 100 μg/ml L-OHP and irradiated with a dose of 2Gy radiations (I/2/50 and I/2/100,
respectively); exposed to 100 μg/ml L-OHP and irradiated with doses of 2Gy (I/2/100) and 4Gy (I/4/100); values are means of three experiments
(*** p < 0.0001, one-way analysis of variance test).
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DE genes induced by L-OHP in the tested cell lines were
comparable our results revealed that 392 genes were mod-
ulated exclusively in Colo320R and 564 genes in HT-29R.
Only a set of 49 genes (sequences) was identified as com-
monly modulated by L-OHP in both cell lines. As 13 se-
quences were uncharacterized, we removed them from
further analysis. Finally, we observed that 9 out of the 36
common genes had different profiles in the two cell lines,
while 27 genes exhibited similar profiles (Table 2).
Identification of the biological pathways modulated
by L-OHP
In order to assess the molecular functions and canonical
pathways [12] modulated by L-OHP in the tested cell
lines we performed the IPA Core Analysis. 334 out of
441 DE genes in Colo320R and 492 out of 612 DE genes
in HT-29R were mapped in IKB. The most significant
cellular and molecular functions affected by L-OHP in
Colo320R and HT-29R cell lines were related to cell
death and survival, cellular growth and proliferation,
DNA replication, cellular movement and cell-to-cell sig-
naling. The analysis of the canonical pathways revealedFigure 3 Representation of lesion scores (LS) of the HT-29 and HT-29
(I/4) of gamma irradiations; exposed to 50 μg/ml or 100 μg/ml L-OHP and
respectively); exposed to 100 μg/ml L-OHP and irradiated with doses of 2G
(* p < 0.05, ** p < 0.001 and *** p < 0.0001, one-way analysis of variance tes15 and 23 canonical pathways significantly modulated by
L-OHP in Colo320R and HT-29R (p < 0.05) cell lines, re-
spectively (Tables 3, 4).
Identification of upstream regulators induced by L-OHP
Using IPA Upstream Regulator Analysis, we identified 10
upstream regulators and their target molecules in HT-29R
dataset. Eight modulators were predicted to be “activated”
(z score > 2, p < 0.01) while 2 modulators were predicted
as “inhibited” (z score < 2, p < 0.01) in response to L-OHP
treatment. These regulators were involved in transcription,
enzyme activity and signal transduction (Table 5). We also
used IPA network overlay function to investigate the rela-
tionships between these upstream regulators and their tar-
get genes (Figure 5). Conversely, we didn’t find significant
upstream regulators in Colo320R dataset.
Validation of microarray results by qRT-PCR
In order to assess the reliability of microarray results, we
considered 9 DE genes as candidates for validation by
qRT-PCR as following: 3 common genes modulated in
both cell lines (PTPRO, KRT18, NDRG1), 3 genes mod-
ulated exclusively in Colo320R (ID1, WIF1 and AVEN)R CC cell lines. Controls (C); irradiated with doses of 2Gy (I/2) and 4Gy
irradiated with a dose of 2Gy radiations (I/2/50 and I/2/100,
y (I/2/100) and 4Gy (I/4/100); values are means of three experiments
t).
Figure 4 Venn diagram of DE genes induced by L-OHP in
tested cell lines. The overlap area indicates the common set of
genes (sequences) modulated by L-OHP in Colo320R and HT-29R
cell lines. In the left area is represented the number of the genes
(392) modulated by L-OHP only in Colo320R, whereas in the right
area is represented the number of the genes (564) uniquely
modulated by the drug in HT-29R cell line.
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spectively (Figures 6, 7). The qRT-PCR results were con-
sistent with the microarray data. A significant and strong
correlation was found between the microarray and qRT-
PCR data for both Colo320 (r = 0.97, p = 0.0009) and
HT29 (r = 0.89, p = 0.016) cell lines (Table 6).
Discussion
Oxaliplatin has antitumoral activity against colorectal,
breast, gastric, renal carcinomas and sarcomas [13] mainly
by forming intrastrand cross-links that block DNA repli-
cation and transcription. Despite the improvements in the
treatment outcome for CC, the tumor cells acquire resist-
ance in time, decreasing the drug’s clinical efficiency.
To address this issue we assessed the morphology,
cytotoxicity, DNA cross-links induction and gene ex-
pression profiles of two colorectal cell lines with identi-
cal origins (adenocarcinoma) with acquired resistance to
L-OHP and their parental lines. According to our results
the L-OHP resistant cells displayed altered cellular and
molecular features as compared to the parental cells. In
addition, notable differences were recorded between the
functions and pathways modulated by L-OHP in the two
tested cell lines.
Some of the morphological alterations we observed here:
pseudopodia formation and adoption of fusiforme shape,
suggesting an epithelial-to-mesenchymal transition (EMT)
and an increased cell-to-cell distance in the HT-29R cells
were also identified by Yang et al. in chemoresistant HT-
29 cells [14]. Part of the embryonic development, EMTap-
pears to be involved in tumor progression and metastasis
[15,16], a process through which cells switch from the
proliferative state to a more primitive, invasive and migra-
tory mode. This conversion was proposed as a potentialmechanism through which cells become chemoresistant,
being known that the cytostatic drugs are more efficient
on the highly proliferative cells [14]. In our study
Colo320R cells displayed (a mesenchymal phenotype, but
adopted some) different characteristics after prolonged
treatment with L-OHP. These cells, usually exposed in
suspension, reacted to the prolonged treatment with the
cytostatic drug by showing an increased tendency of ad-
herence. Although our findings demonstrated different ad-
aptations of the tested cell lines to the L-OHP treatment,
a common feature was obvious: the alteration of the cellu-
lar adhesion complexes, suggesting higher invasiveness
and attachment capacity.
The IC50 values obtained in the present study revealed
that the prolonged treatment of the cells with increasing
concentrations of the drug, up to the clinically relevant
concentration (2 μmol/l), induced resistance in the treated
cells as compared to the parental ones. Our results are
comparable to other previous findings on parental and re-
sistant Colo320 cells [11] and on sensitive Colo320 and
HT-29 cells [7,17].
The CA findings confirmed different behaviors of the
tested cell lines to the prolonged treatment to L-OHP.
Both parental cell lines were sensitive to 2 Gy of gamma
irradiation and displayed consistent DNA damages. The
administration of L-OHP prior to irradiation revealed
higher cross-links formation in the Colo320 cell line as
compared to HT-29. These results are in agreement with
the cytotoxicity findings which suggested that Colo320 cell
line is more sensitive to L-OHP than HT-29. An intriguing
fact was the lack of response to the same dose of ionizing
radiation (2 Gy) in the chemoresistant cell groups. More-
over, the higher dose of irradiation (4 Gy) caused DNA le-
sions only in HT-29R cells, while Colo320R remained
unresponsive. These results suggest that acquired resist-
ance to a chemotherapeutic agent could have activated
general resistance pathways that impart resistance to mul-
tiple agents, including irradiation. Another potential ex-
planation for the lack of the response to irradiation could
be the presence of some free radical scavengers that might
have contributed to the resistance to irradiation. The
redox homeostasis of the cells was previously implicated
in chemo-resistance. It is commonly accepted that the
sensitivity of tumor cells to L-OHP, can be influenced by
gluthatione and gluthatione related enzymes [18]. Thus,
gluthatione S-tranferase (GST) catalyses the conjugation
of gluthatione to genotoxic compounds, preventing DNA-
damage and adduct formation [19]. Gluthatione system
limits the cytotoxic activity of oxaliplatin by modifying the
production of cellular reactive species (ROS) [20]. If ROS
production decreases, also the cytotoxicity of the chemo-
therapy agent decreases. Additionally, ROS act also as crit-
ical mediators in ionizing radiation-induced cell killing
[21]. Moreover, some subsets of tumor cells were shown
Table 2 Common core set of DE genes modulated by L-OHP in the tested cell lines







TMX4 Thioredoxin-related transmembrane protein 4 3.43 1.18E-06 2.73 6.57E-10
PTPRO Protein tyrosine phosphatase, receptor type, O 1.58 2.58E-05 1.85 1.93E-08
LGALS1 Lectin, galactoside-binding, soluble, 12 2.71 7.32E-07 1.58 3.62E-09
KRT18 Keratin 18, transcript variant 1 1.87 7.29E-08 1.54 1.81E-07
THC2739159 ALU8_HUMAN (P39195) Alu subfamily SX sequence contamination
warning entry, partial (8%)
2.04 2.48E-04 1.77 7.46E-08
XR_019191 PREDICTED: Homo sapiens similar to Keratin, type I cytoskeletal 18
(Cytokeratin-18) (CK-18) (Keratin-18) (K18) (LOC121054), mRNA [XR_019191]
2.00 7.97E-09 1.56 6.13E-08
XR_017030 Heat-shock protein beta-1 (HspB1) (Heat shock 27 kDa protein) (HSP 27) (Stress responsive
protein 27) (SRP27) (Estrogen-regulated 24 kDa protein) (28 kDa heat shock protein)
1.99 1.30E-08 1.53 8.82E-08
XR_018843 PREDICTED: Homo sapiens similar to Keratin, type I cytoskeletal 18 (Cytokeratin-18)
(CK-18) (Keratin-18) (K18) (LOC649233), mRNA [XR_018843
1.93 8.66E-07 1.71 1.52E-05
AK022045 Homo sapiens cDNA FLJ11983 fis, clone HEMBB1001337 1.80 1.24E-05 1.82 6.51E-09
THC2611661 RR12_SPIMX (P42344) Chloroplast 30S ribosomal protein S12, partial (11%) 1.80 2.24E-04 1.51 8.50E-08
THC2524582 Q5U0N8_HUMAN (Q5U0N8) Keratin 18 (Cell proliferation-inducing protein 46),
partial (46%) [THC2524582]
1.75 3.60E-07 1.57 8.96E-07
NM_173624 KRT18P55 keratin 18 pseudogene 55 1.72 3.34E-07 1.57 1.13E-06
XR_018670 PREDICTED: Homo sapiens similar to Keratin, type I cytoskeletal 18 (Cytokeratin-18)
(CK-18) (Keratin-18) (K18) (LOC643471), mRNA [XR_018670]
1.72 1.71E-07 1.51 6.88E-08
XR_015605 PREDICTED: similar to Keratin, type I cytoskeletal 18 (Cytokeratin-18)
(CK-18) (Keratin-18) (K18) (LOC731794), mRNA
1.71 3.34E-07 1.51 4.97E-07
BC048264 Homo sapiens hypothetical protein LOC283666, mRNA (cDNA clone IMAGE:4415549),
partial cds
1.71 3.63E-05 1.88 1.27E-08
XR_018311 PREDICTED: Homo sapiens similar to Keratin, type I cytoskeletal 18 (Cytokeratin-18)
(CK-18) (Keratin-18) (K18) (LOC139060), mRNA [XR_018311]
1.67 2.29E-05 1.55 1.23E-07
NM_001007139 Homo sapiens insulin-like growth factor 2 (somatomedin A) (IGF2),
transcript variant 2, mRNA
2.08 7.10E-06 1.53 6.85E-09
THC2663167 ALU1_HUMAN (P39188) Alu subfamily J sequence contamination warning entry,
partial (5%) [THC2663167]
2.07 3.24E-04 1.55 1.17E-08
Class B
IL1RAP Interleukin 1 receptor accessory protein −1.61 2.86E-05 −1.53 4.67E-07
GRB14 Growth factor receptor-bound protein 14 −1.73 3.97E-07 −1.56 4.16E-09
RBPMS2 RNA binding protein with multiple splicing 2 −1.60 1.19E-04 −1.58 8.16E-07
RHOBTB1 Rho-related BTB domain containing 1 −1.58 7.77E-05 −1.67 3.44E-07
CD302 CD302 molecule −1.88 2.57E-06 −1.68 1.07E-09
HMGCS1 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 −1.56 2.38E-04 −1.73 2.77E-07
POLR1D Polymerase (RNA) I polypeptide D, 16 kDa −1.52 1.44E-06 −1.74 3.02E-10
CA12 Carbonic anhydrase XII (CA12), transcript variant 1 −2.60 2.55E-10 −1.95 4.95E-11
AKR1B1 Aldo-keto reductase family 1, member B10 −1.91 1.78E-07 −3.18 2.54E-12
Class C
IFITM3 Interferon induced transmembrane protein 3 −1.74 1.87E-07 2.08 1.28E-11
IFITM4P Interferon induced transmembrane protein 4 pseudogene −1.60 3.88E-07 1.78 1.28E-08
IFIH1 Interferon induced with helicase C domain 1 −2.64 1.40E-07 1.67 4.51E-08
CFHR1 Complement factor H-related 1 −2.64 4.32E-09 1.61 1.70E-08
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Table 2 Common core set of DE genes modulated by L-OHP in the tested cell lines (Continued)
Class D
CAMK2N1 Calcium/calmodulin-dependent protein kinase II inhibitor 1 1.64 1.33E-07 −1.55 3.97E-07
SAMD5 Sterile alpha motif domain containing 5 1.51 2.41E-04 −1.73 8.09E-09
NDRG1 N-myc downstream regulated 1 1.79 7.96E-07 −1.75 1.55E-07
COL9A3 Collagen, type IX, alpha 3 1.91 3.92E-06 −1.79 6.45E-09
IRX5 Iroquois homeobox 5 1.88 1.94E-07 −1.53 9.56E-08
Classes A and B represent up- respectively down-regulated genes induced by L-OHP in Colo320R and HT-29R. Classes C and D include antagonist DE genes
induced by L-OHP in the tested cell lines.
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http://www.biomedcentral.com/1471-2164/14/480to possess lower levels of ROS and enhanced ROS defense,
which contributed to their radioresistance [22]. Therefore,
a link between redox homeostasis and cells’ resistance to
chemo/radiotherapy is conceivable. Given that this subset
of cells, with increased radioresistance was ascertained as
cancer stem cells (CSC), we can presume that another
cause of the cells’ peculiar response to ionizing irradiation
could be the phenotypic characteristics of the cells. Resist-
ant cells in our study have switched their morphology, as
our microscopy findings suggest it. It is also possible that
this population might have adopted stem-like characters.
Literature data sustain that cancer stem cells (CSC), ex-
pressing CD133+ marker manifest resistance to irradiation
with 2, 5 Gy unlike CD133- non stem-cells [23]. This dif-
ferent behavior was explained by the activation of the
DNA damage checkpoint more efficiently in CSC than in
tumor cells without stem cells properties, due to the acti-
vation of Chk1 and Chk2 checkpoint kinases [24]. We also
demonstrated in the present study the phosphorylation of
Chk2 and p53, due to activation of ataxia-telangiectasiaTable 3 Top canonical pathways modulated by L-OHP in Colo
Canonical pathways Colo320R p-value Log Ra
Aryl hydrocarbon receptor signaling 1E-03 5.59E-
HGF Signaling 3E-03 6.67E-
LPS/IL-1 mediated inhibition of RXR function 7E-03 4.18E-
Hepatic fibrosis/hepatic stellate cell activation 1.6E-02 4.79E-
Retinoate biosynthesis I 1.8E-02 7.89E-
Methylglyoxal degradation III 1.68E-02 8.7E-0
S-methyl-5′-thioadenosine degradation II 1.9E-02 1.67E-
Histamine biosynthesis 1.9E-02 3.33E-
Retinol biosynthesis 2.5E-02 4.92E-
Cell Cycle: G1/S checkpoint regulation 2.7E-02 6.06E-
The visual cycle 2.9E-02 7.14E-
PXR/RXR activation 3.2E-02 4.6E-0
Glutamine biosynthesis I 3.8E-02 1.25E-
Thyroid cancer signaling 4.2E-02 7.14E-
Mitochondrial L-carnitine shuttle pathway 4.2E-02 9.09E-mutated gene ATM, this being activated by an apoptosis
caspase activation inhibitor (AVEN). Activation of AVEN
being evident in Colo320R cell line and not in HT-29R
may be a possible explanation for the differential behavior
of these cells as compared to HT-29R (i.e. HT-29R
responded to 4 Gy, unlike Colo320, which remained resist-
ant). The significantly different gene expression profiles of
the tested cell lines, sustained also by cytotoxicity suggest
that these cells have completely different genomic pat-
terns, which may explain also their different behavior to-
wards gamma irradiation. The fact that in Colo320R cell
line we still could detect cross-links confirms once more
the higher sensitivity of this cell line to L-OHP as com-
pared to HT-29. In a previous study we observed changes
in the comet tails length according to the degree of the
treatment with L-OHP, indicating the presence or absence
of the DNA cross-links induced by L-OHP on the tested
cell lines [11]. In another study we induced standardized
DNA strand breaks via ionizing irradiation and compared
the cross-links formation capacity of L-OHP vs CDDP in320R
tio Molecules
02 HSPB3, CDKN2A, MYC, FOS, GSTM2, ALDH1A1, NQO1, TGFB2, HSPB1
02 CDKN2A, MET, FOS, MAP3K6, MAP3K13, ETS2, ELK3
02 CHST2, ABCB1, GSTM2, ALDH1A1, SLC27A2, HS3ST1, CPT1C,
PLTP, HMGCS1, IL1RAP
02 MET, TIMP1, ACTA2, TGFB2, IGFBP5, IL1RAP, COL3A1




02 DHRS3, RBP7, LPL
02 CDKN2A, MYC, HDAC9, TGFB2
02 DHRS3, RBP7
2 ABCB1, GSTM2, ALDH1A1, FOXO1
01 GLUL
02 PPARG, MYC, NTF3
02 SLC27A2, CPT1C
Table 4 Top canonical pathways modulated by L-OHP in HT-29R
Canonical pathways HT-29R p-value Log ratio Molecules
Interferon signaling 2,51E-05 1.94E-01 IFIT3, IFIT1, IFITM1, MX1, IRF9, PSMB8, STAT1
Methylglyoxal degradation III 2,04E-04 1.74E-01 AKR7A3, AKR1C1/AKR1C2, AKR1B10, AKR1B1
Cholesterol biosynthesis I 4,17E-04 1E-01 SQLE, DHCR7, MSMO1, CYP51A1
Cholesterol biosynthesis II (via 24,25-dihydrolanosterol) 4,17E-04 1E-01 SQLE, DHCR7, MSMO1, CYP51A1
Cholesterol biosynthesis III (via Desmosterol) 4,17E-04 1E-01 SQLE, DHCR7, MSMO1, CYP51A1
LXR/RXR activation 7,76E-04 8.09E-02 SCD, TTR, LDLR, SREBF1, AMBP, SERPINA1, PTGS2, TLR3,
IL1RAP, CYP51A1, AGT
Mevalonate pathway I 4,47E-03 1.07E-01 IDI1, HMGCS2, HMGCS1
Creatine-phosphate biosynthesis 4,90E-03 3.33E-01 CKB, CKMT1A/CKMT1B, LCMT2
Activation of IRF by Cytosolic pattern
recognition receptors
5,75E-03 8.33E-02 DHX58, IFIH1, IRF9, STAT1, IFIT2, ISG15
Tryptophan degradation X (Mammalian, via Tryptamine) 1,05E-02 1.03E-01 ALDH1A3, DDC, MAOA
Zymosterol biosynthesis 1,17E-02 9.09E-02 MSMO1, CYP51A1
Maturity onset diabetes of young (MODY) signaling 1,95E-02 9.68E-02 FOXA2, FABP1, HNF4A
Eicosanoid signaling 2,19E-02 6.25E-02 DPEP1, PNPLA3, RARRES3, PTGS2, ALOX5
Ketogenesis 2,69E-02 9.52E-02 HMGCS2, HMGCS1
Acyl-CoA hydrolysis 3,31E-02 1.25E-01 ACOT4, HNF4A
PXR/RXR activation 3,47E-02 5.75E-02 SCD, NR0B2, CYP2B6, HMGCS2, HNF4A
Colorectal cancer metastasis signaling 3,89E-02 4.67E-02 VEGFA, MMP7, RND3, TGFB1, FZD3, GNB5, TGFB2,
PTGS2, TLR3, STAT1, FNBP1, WNT5A
Aryl hydrocarbon receptor signaling 4,17E-02 4.97E-02 TGM2, TFF1, NR0B2, ALDH1A3, TGFB1, TGFB2, ALDH18A1,NRIP1
p38 MAPK signaling 4,27E-02 5.98E-02 DDIT3, TGFB1, TGFB2, MKNK2, RPS6KA2, STAT1, IL1RAP
Choline biosynthesis III 4.64E-02 9.09E-02 CHPT1,PLD1
Histamine degradation 4.64E-02 6.9E-02 ALDH1A3,ABP1
Adenosine nucleotides degradation II 4.64E-02 8E-02 NT5E, ADA
Wnt/β-catenin signaling 5E-02 5.2E-02 MMP7, CDH3, TGFB1, PPP2R3A, TGFBR3, FZD3, CD44,
TGFB2, WNT5A
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http://www.biomedcentral.com/1471-2164/14/4803 CC cell lines (Colo320, Caco-2 and HT-29) [17]. Our re-
sults showed higher cytotoxicity and cross-links formation
for L-OHP vs CDDP in the tested cell lines, in spite of
lower cellular uptake. In the present study, we determined
indirectly the cross-links formation on the irradiation-
damaged DNA and demonstrated that L-OHP resistant
cells form fewer cross-links than the parental ones, in ac-
cordance with the sensitivity of the tested cells to the cyto-
toxic drug. Similar studies were performed by others
treating with CDDP the healthy human leukocytes [25] and
ovarian carcinoma cells [26] and using L-OHP treatment
on lymphocytes and lung carcinoma cell lines [27]. These
studies used UV-C, methyl methanesulfonate and ionizing
radiations, respectively, as DNA strand-breaking agents and
detected DNA cross-links using an in vitro measure of the
cells’ chemosensitivity to the tested compounds.
Our microarray data were in agreement with the
morphology, cytotxicity and DNA lesions findings show-
ing that the prolonged treatment with L-OHP triggered
different patterns in the transcriptional profiles of thetwo tested cell lines. To our knowledge, there are no
similar studies to highlight the differences between the
molecular patterns of these two resistant cell lines how-
ever there are genomics studies that evaluated the resist-
ance to treatment either in Colo320 or HT-29 [28].
Considering the common origin of these cell lines
(adenocarcinomas) and the mechanism of action of L-
OHP which blocks DNA replication and transcription
through the formation of intra-strand DNA adducts, we
would expect at least to some extent, similar molecular
and cellular behavior. Surprisingly, our microarray data
have revealed only a common core set of 36 genes mod-
ulated more than 1.5-fold in both cell lines (p < 0.05) of
which just 27 genes exhibited similar profiles (Table 2).
These results could be partly explained by the distinct
morphology (suspension vs. adherent) and by the intrinsic
differences of the two cell lines which emphasize the com-
plexity of the processes that control the resistance acquire-
ment to this cytostatic drug. Our data revealed that
L-OHP modulates genes involved in the regulation of
Table 5 Upstream regulators induced by L-OHP treatment in HT-29R
Upstream
regulator




Target molecules in dataset
TGM2 0.968 Enzyme Activated 4.762 8.90E-09 DDX60, DDX60L, DEFA1, HIP1, IFI6, IFIT1, IFIT2, IFIT3, IFIT5,
IRF9, MT2A, OAS3, OASL, PARP9, PHLDA1, PLSCR1, RARRES3,
RUNX2, SAMD9L, SLFN5, STAT1, TGFB1, XAF1
STAT1 0.855 Transcription regulator Activated 3.592 1.47E-08 AGT, ALDH1A3,CLIC5, DPP4, HERC6, IFI27, IFI6, IFIT1, IFIT2,
IFITM1, IRF9, ISG15, KCTD12, PSMB8, PSMB9, PTGS2, RUNX1,
SLFN5, STAT1, TLR3, TYMP, USP18
TLR3 0.624 Transmembrane receptor Activated 3.392 5.85E-07 DHX58, IFI44, IFI44L, IFI6, IFIH1, IFIT1,IFIT2, IFIT3, IFNE, ISG15,
MX1, MX2, OASL, PHLDA1, PLK2, PTGS2, STAT1, TLR3, USP18
INSIG1 −2.061 Other Activated 3.039 1.74E-06 CXCR4, CYP51A1, DHCR7, HMGCS1, HMGCS2, IDI1, LDLR,
PLD1, SCD, SQLE, SREBF1, STARD4,TGFB1
NFATC2 0.635 Transcription regulator Activated 3.019 3.84E-05 IFIT2, ISG15, LMO4, MX1, OASL, PLD1, PLK2, PTGS2, SH3BP5,
SLCO3A1, STAT1, TGFB1,T LR3
IFNE 0.861 Cytokine Activated 2.804 2.07E-07 IFIH1, IFIT2, MX2, PTGS2, RARRES3, STAT1, TLR3, USP18
PARP9 1.087 Other Activated 2.433 1.24E-06 IFI44, IFIT1, IFIT2, IFIT3, ISG15, STAT1
IFIH1 0.742 Enzyme Activated 2.190 2.68E-04 BST2, ISG15, MX1, PHLDA1, RND3
SREBF1 −0.624 Transcription regulator Inhibited −2.980 1.36E-07 CAMK1D, CYP51A1, DHCR7, HMGCS1, HNF4A, IDI1, INSIG1,
LDLR, MSMO1, NR0B2, PNPLA3, PTGS2, SCD, SQLE, SREBF1,
STARD4,T GFB1, VEGFA
USP18 0.941 Peptidase Inhibited −2.219 5.62E-05 IFI6, IFITM3, IRF9, ISG15, MX1
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death and survival, cellular growth and proliferation, cellu-
lar movement and cell-to-cell signaling and interaction.
The microarray analysis showed upregulation of kera-
tin 18 (KRT18) and protein tyrosine phosphatase recep-
tor type O (PTPRO), both being involved in apoptosis.
The microarray results validated by qRT-PCR con-
firmed a significant overexpression of these genes in
both HT-29R and Colo320R (Table 6). KRT18 was pre-
viously identified as being upregulated in colon carcin-
oma cells [29]. Increased KRT18 expression has been
reported to inhibit cytokine-induced death of cervical can-
cer cells [30] but there are no evidences about the role of
KRT18 in L-OHP-induced resistance in CC. PTPRO is a
member of family of receptor-type protein tyrosine phos-
phatases with multiple tissue-specific functions including
inhibition of cell proliferation and promoting of apoptosis.
PTPRO was identified as a target gene of Wnt/β-catenin
signaling [31] and a novel regulator of ERBB2 signaling for
mammary epithelial transformation [32]. Ramaswamy
et al. observed increased expression of PTPRO in breast
cancer following the treatment with tamoxifen [33]. In CC
there are no studies describing the implication of PTPRO
in drug resistance, but this gene was found to be methyl-
ated in colon tumors [34].
The core set of common DE genes also included some
members of interferon - inducible transmembrane gene
(IFTIM), whose transmembrane proteins are involved
in the homotypic cell adhesion functions of interfer-
on (IFN) [35]. We identified significant upregulation ofIFITM3, IFITM4P and IFIH1 in HT29R and downreg-
ulation of these genes in Colo320R (Table 2, Class C).
The overexpression of IFTIM3 is related to an increased
proliferation and metastasis of human colon cancer
cells. Andreu et al. identified high endogenous levels of
IFITM3 in HT29 cells with APC mutated gene [36]. The
authors demonstrated that induction of wild-type APC
causes a reduction on IFTIM3 genes within 24 hours. In
another study, Ghaleb et al. demonstrated that IFITM3
transcription is dependent on activation of Wnt/β-catenin
signaling, in intestinal epithelium [37]. This study appears
to be in concordance with our results. Analyzing the ca-
nonical pathways for both cell lines we noticed an
increased activity for Wnt/β-catenin signaling in HT29R
but not in Colo320R (Tables 3, 4). These findings sup-
port the morphological observations which suggest an
epithelial-to-mesenchymal transition in HT-29R cells.
N-myc downstream regulated 1 (NDRG1) gene had
a conflicting expression in the two cell lines, being
overexpressed in Colo320R and underexpressed in HT-
29R (Table 2, Class D). qRT-PCR confirmed upregulation
of NDRG1 in Colo320R and downregulation in HT-29R
as a result of prolonged treatment with L-OHP (Table 6).
The protein encoded by NDRG1 is implicated in p53-
mediated caspase activation and apoptosis. Strzelczyk
et al. showed correlation between low levels of NDRG1
gene expression and poor prognosis and survival for pa-
tients with CC [38]. These results could suggest that lower
level of NDRG1 in HT29R than in Colo320R could be re-
lated to a more resistant phenotype.
Figure 5 IPA Network. The network displays the relationship between upstream regulators and their target molecules in HT-29R cell line. The
colors indicate the level of mRNA expression: upregulated genes are represented in red and downregulated genes in green.
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http://www.biomedcentral.com/1471-2164/14/480In response to treatment with cytostatic drugs, cells
undergo apoptosis according to the drug-induced DNA
damage and the cells’ capacity of DNA repair and survival.
In Colo320R, the apoptotic process was mediated by genes
involved in caspase modulation and cell cycle regulation.
Our results showed that apoptosis caspase activation in-
hibitor (AVEN), Galectin-3 (LGALS3) and nucleolar pro-
tein 3 (NOL3) were overexpressed in this cell line. AVEN
represents an activator for ataxia-telangiectasia mutated
gene (ATM) which has an important role in the repair of
DNA breaks [39]. Cell-cycle arrest induced by DNA dam-
age depends on activation of ATM protein kinase, which
phosphorylates cell-cycle effectors such as CHEK2 and p53
in order to inhibit cell-cycle progression. LGALS3 and
NOL3 are known as downregulators of the enzyme activ-
ities of caspase 2, caspase 8 and tumor protein p53.
LGALS3 is involved in the resistance of human coloncancers by blocking the death-inducing signaling complex
(DISC) formation and recruitment of the apoptosis-
initiating protease, procaspase-8 [40]. Conversely, the in-
creased expression of NOL3 reduced the TRAIL-induced
apoptosis in SW480 CC cells [41]. We observed an inhib-
ition of cyclin-dependent kinase inhibitor 2A (CDKN2A)
and WNT inhibitory factor 1 (WIF1) tumor suppressor
genes in Colo320R following the L-OHP treatment. The
lack of function of these genes was associated with tumor
cell progression [42,43].
In addition to the inhibition of apoptosis, our results
pointed out to the activation of the mechanisms involved
in promoting cell survival and tumor progression in
Colo320R. We observed overexpression of insulin-like
growth factor 2 (IGF2), mitogen-activated protein kinase
kinase kinase 6 (MAP3K6), FBJ murine osteosarcoma viral
oncogene homolog (FOS), inhibitor of DNA binding 1
Figure 6 qRT-PCR validation of microarray results in Colo320
cell line. The bars represent the mean (± SD) of three biological
replicates for every gene. All genes were normalized to 18 rRNA and
fold regulation was calculated relative to Colo320S. (* p < 0.05,
** p < 0.01, *** p < 0.001).
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http://www.biomedcentral.com/1471-2164/14/480genes (ID1), involved especially in signal transduction on
MAP kinase cascade. Our data are in agreement with the
literature data concerning the role and implication of
these molecules in CC [44-46]. We also noticed
downregulation of the peroxisome proliferator-activated
receptor γ (PPARG) in Colo320R. Inhibition of PPARG
promotes the cell proliferation and leads to the expression
of c-myc and cyclin D1 genes as well as of the beta-
catenin protein in the colon epithelium [47].
As we underlined above, the genes evidenced with
microarray analysis were quite different between the two
tested cell lines, therefore we expected apoptosis in HT-
29R to be modulated by a different set of genes comparedFigure 7 qRT-PCR validation of microarray results in HT-29 cell
line. The bars represent the mean (± SD) of three biological replicates
for every gene. All genes were normalized to 18 rRNA and fold
regulation was calculated relative to HT-29S. (* p < 0.05, ** p < 0.01,
*** p < 0.001).to those identified for Colo320R. The ineffective induc-
tion of apoptosis in HT-29R cell line was mediated by
genes involved in Bcl-2 modulation. One of these genes,
serum/glucocorticoid regulated kinase 1 (SGK1) is in-
volved in phosphorylation and inactivation of the apop-
totic transcription factor forkhead box O3 (FKHRL1),
that upregulates death receptor components such as
tumor necrosis factor receptor superfamily, member 10 b
(TNFRSF10B) and proapoptotic Bcl-2 proteins such as
Pim [48]. Another member of Bcl-2 family upregulated in
HT-29R cell line, XIAP associated factor 1 (XAF1), has
an important role in modulation of apoptosis in tumor
cells by inhibiting the caspase-3 activity [49].
We also noticed that the L-OHP resistance in HT-29R
was promoted by the overexpression of some important
modulators involved in cell proliferation such as:
midkine (MDK), cysteine-rich, angiogenic inducer 61
(CYR61), proliferating cell nuclear antigen (PCNA),
transforming growth factor beta 1 (TGFB1), spleen
tyrosine kinase (SYK) and prostaglandin-endoperoxide
synthase 2 (PTGS2). Upregulation of MDK was corre-
lated with tumor progression in oral squamous cell car-
cinoma [50], but to our knowledge, MDK was not found
to be expressed in CC. CYR61 has multiple roles in
tumor growth, adhesion and migration, its role as posi-
tive growth-regulator in CC being previously described
[51]. PTGS2 and PCNA represent two important mole-
cules for the progression of CC and treatment strategy
[52] and increased levels of PTGS2 were associated with
enhanced tumor cell proliferation and tumorigenesis [53].
Subsequently, we paid attention to upstream regula-
tors in attempt to explain the different phenotypes in-
duced by L-OHP in the two tested CC cell lines.
Although statistically significant results were not found
in Colo320R, we identified 10 upstream regulators in
HT29R, eight out of them with “activated” and two with
“inhibited” predictions (Table 5). Among the top predicted
regulators in HT29R dataset, the signal transducer and ac-
tivator of transcription 1 (STAT1) appears to be signifi-
cantly activated (z-score = 3.592) by L-OHP treatment, its
targets being highly enriched in the data (p = 1.47E-08).
STAT1 represents an important activator of transcription
in CC [54]. The activation of STAT1 in HT-29R was asso-
ciated with an increased transcriptional activity in a large
number of associated interferon-inducible genes (IFITM1,
IFIT3, IFIT1, IFI6, IFI27) (Figure 5). We observed that
STAT1 is in turn activated by IFNE, NFATC2 and TGM2.
The upregulation of STAT1 mediated by interferon epsilon
(IFNE) was described on cervical cancer cells [55], but to
our knowledge, there are no studies describing the role of
IFNE in CC. Nuclear factor of activated T cells (NFATC2)
is a transcription factor with an important role in the tran-
scriptional regulation of the immune response. Its role in
CC in promoting carcinoma migration and invasion was
Table 6 The correlation between microarray and qRT-PCR results
Accession # Gene
symbol
Gene name Microarray qRT-PCR Pearson
correlation r (p)Fold regulation p value Fold regulation p value
Colo320R
NM_030667 PTPRO Protein tyrosine phosphatase, receptor type, O 1.58 2.58E-05 2.36 3E-04 0.97 (9E-04)
NM_000224 KRT18 Keratin 18, transcript variant 1 1.87 7.29E-08 2.71 2E-04
NM_006096 NDRG1 N-myc downstream regulated 1 1.78 7.96E-07 1.55 0.04
NM_020371 AVEN Apoptosis, caspase activation inhibitor 1.50 4.74E-06 1.79 5E-03
NM_007191 WIF1 WNT inhibitory factor 1 −1.72 2.35E-07 −2.08 3E-04
NM_002165 ID1 Inhibitor of DNA binding 1, dominant negative
helix-loop-helix protein
2.20 1.97E-08 2.45 4E-04
HT-29R
NM_030667 PTPRO Protein tyrosine phosphatase, receptor type, O 1.85 1.93E-08 4.22 2.70E-05 0.89 (1.6E-02)
NM_000224 KRT18 Keratin 18, transcript variant 1 1.54 1.81E-07 1.31 4E-04
NM_006096 NDRG1 N-myc downstream regulated 1 −1.75 1.55E-07 −2.17 4E-04
NM_000660 TGFB1 Transforming growth factor, beta 1 1.66 1.10E-09 2.12 0.001
NM_001012334 MDK Midkine (neurite growth-promoting factor 2) 2.22 3.51E-11 4.29 0.001
NM_001554 CYR61 Cysteine-rich, angiogenic inducer, 61 1.56 5.62E-09 1.72 4.49E-05
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http://www.biomedcentral.com/1471-2164/14/480previously demonstrated in in vitro and in vivo studies
[56,57]. Our data confirm the implication of NAFTC2
in HT-29R CC cell line as an important upstream
regulator (z-score = 3.019, p = 3.84E-05). Transglutami-
nase 2 (TGM2) is an enzyme involved in cell prolifera-
tion, differentiation and apoptosis and could mediate
chemoresistance in cancer cells [58]. TGM2 was pro-
posed by Miyoshi et al. as a predictive marker for prog-
nosis and therapeutic target in CC [59]. In our study,
TGM2 was the most notably activated upstream regulator
identified in HT29R cell lines (z-score = 4.762, p = 8.9E-09)
(Table 5). Recent studies have shown that TGM2 pro-
motes drug resistance and invasion by inducing a stem
cell-like phenotype in ovarian and breast cancer [60,61].
Our results showed that overexpression of TGM2 and
NAFTC2 induced TGFB1 activation. High level of TGFB1
expression in HT-29R obtained by microarray was
confirmed by qRT-PCR (Table 6). TGFB1 is a well-
characterized inducer of EMT in ovarian cancer and
human squamous cell carcinoma cells, resulting in in-
creased cell migration and invasion [62,63]. Consider-
ing all these findings, upregulation of TGM2, NAFTC2
and TGFB1 in HT29R but not in Colo320R could ex-
plain the induction of EMT and acquiring a more re-
sistant phenotype in HT29R.
Another target of TGM2, poly (ADP-ribose) polymer-
ase family member 9 (PARP9) upstream modulator was
significantly activated (z-score = 2.433, p = 1.24E-06) in
HT-29R and acts as regulator of STAT1. PARP9 was
identified as overexpressed in chemoresistant, diffuse
large B-cell lymphomas (DLBCLs) [64], but there is no
data concerning the implication of PARP9 in CC.Conclusions
In our study CC cells adopted several cellular and mo-
lecular alterations during the prolonged treatment with
L-OHP which led to resistance to this drug. L-OHP re-
sistant cells displayed altered morphologies, higher inva-
siveness and metastatic capacities, lower cytotoxicities,
formed fewer Pt-DNA cross-links and had different gene
expression profiles as compared to the sensitive ones.
More disrupted functions and pathways were identified
in HT-29R than in Colo320R cells, involving genes re-
sponsible for apoptosis inhibition, cellular proliferation
and epithelial-to-mesenchymal transition. These find-
ings, in agreement with the morphological and cytotox-
icity results and the main upstream regulators identified
for HT-29R, but not for Colo320R could explain the
more resistant phenotype in HT-29R than in Colo320R
cell line.
Therefore, we can conclude that prolonged therapy with
L-OHP induces different cellular and molecular chemo-
resistance patterns in CC cells of identical origins (adeno-
carcinomas). The set of genes modulated by L-OHP and
the upstream regulators revealed in our study explain the
diverse behavior of the cancer cells to prolonged therapy
with L-OHP, moreover could help us to identify some po-
tential means to reverse chemoresistance and consequently
to improve the outcome of therapy in CC.
Methods
Cell lines and cultures
Colo320 and HT-29 human CC cell lines were obtained
from the European Collection of Cell Cultures (ECACC).
Colo320 was cultured in RPMI-1640 and HT-29 in
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Fetal Calf Serum 10%, L-glutamin and penicillin-strep
tomycin (Sigma-Aldrich, St. Louis, MO). Experiments
were done at 70–80% cell confluence and confirmed in at
least three independent experiments.Development of L-OHP-resistant cell lines
Resistance to L-OHP (Actavis, Bucharest, Romania) was
induced by exposing the cells to increasing concentra-
tions of the drug. The initial dose was 0.01 μg/ml and
the final concentration (0.87 μg/ml) corresponded to the
clinically relevant plasma concentration of L-OHP
(2 μmol/l) [14]. The resistant variant of Colo320
(Colo320R) was obtained and described previously [11].
For the HT-29 cell line we used the same procedure, se-
quentially increasing concentrations of the drug (with
0.05 μg/ml) being added to the cell culture at every sec-
ond passage. The surviving cells were grown and propa-
gated every 4–5 days. For both cell lines two groups
were considered for investigations: parental (Colo320
and HT-29) and cells with induced chemoresistance
(Colo320R and HT-29R). All groups were cultivated in
specific media, for the chemoresistant cells the culture
media being supplemented with L-OHP 0.87 μg/ml at
every second passage.Morphology analysis
The morphological analysis of the cells was performed
with a light microscope (Carl Zeiss MicroImaging GmbH,
Gottingen, Germany), with digital photographic capability.
The microscopic images of cells were compared with re-
spect to morphological characteristics (shape, polarity,
intercellular distances and presence of pseudopodia).Evaluation of L-OHP cytotoxicity
The MTS/PMS (Promega Corporation, Madison, WI,
USA) colorimetric cell proliferation assay was used for the
Colo320 and Colo320R suspension-type and MTT test
(Sigma-Aldrich, St. Louis, MO, USA) for HT-29 and HT-
29R adherent cells, in order to simplify the solubilization
procedures for the suspension-type cell lines [65]. Briefly,
cells were seeded in triplicate in 96-well flat-bottom plates,
at a cell population density of 15x103 and 2x104 for MTS/
PMS and MTT assays, respectively. After 24 h, variable
concentrations of L-OHP (0.001-300 μg/ml) were added
and the cells were incubated for additional 24 h. Absor-
bances were recorded with an ELISA plate reader, at
490 nm wavelength (Tecan Sunrise, Grödig/Salzburg,
Austria). The half maximal inhibitory concentration (IC50)
values were calculated as the concentrations corresponding
to a 50% reduction of the cellular growth.Evaluation of cross-links formation
Platinum-DNA cross-links induced by L-OHP on the se-
lected cell lines were determined indirectly with CA.
Single strand-breaks were induced in the L-OHP-treated
DNA via ionizing radiation as secondary genotoxic
agent. We evidenced the L-OHP-DNA cross-links by
quantifying the reduction in the single-strand breaks
provoked by the ionizing radiations subsequent to L-
OHP treatment. Briefly, the selected cell groups were
seeded in triplicate in 24-well plates at a cell population
density of 4x105. After 24 h incubation, cells were either
irradiated with doses of 2 Gy or 4 Gy gamma radiations
using a Co60 source (Theratron 1000, Theratronics, Inc.,
Ottawa, Ontario, Canada), or exposed first to L-OHP
(50 or 100 μg/ml) for 2 h and afterward gamma-
irradiated. Dose rate of the applied radiation source was
1, 98 Gy/min. The cells were transported from the site
of the irradiation to the CA laboratory on ice, in order
to avoid DNA repair process. CA was performed under
alkaline conditions according to Tice’s protocol [66].
The images of the cell’s nuclei were evaluated for DNA
migration (the level of strand breaks) using a fluores-
cence microscope (Nikon Eclipse E600, Tokyo, Japan),
equipped with 510–560 nm excitation and 590 nm bar-
rier filters. 200 cells from each group were scored and
assigned to different lesion classes using the Collins’
classification method [67]. For each group a lesion score
(LS) was calculated, based on the number of the cells
assigned to each comet classes. LS was expressed as ar-
bitrary units (AU) and the detailed description of the
calculation of LS was made elsewhere [11].
Microarray expression profiling
The gene expression profiling of the parental (Colo320 and
HT-29) and L-OHP-resistant (Colo320R and HT-29R) cell
lines was assessed with 4x44k Whole Human Genome
Oligo Microarray G4112F slides (Agilent Technologies,
Santa Clara, CA, USA) using two-color design. Three bio-
logical replicates of each cell lines, both parental and resist-
ant, were tested in order to identify genes implicated in the
L-OHP-resistance acquiring process. Total RNA was iso-
lated using TriReagent (Sigma-Aldrich, St. Louis, MO,
USA) and purified with RNeasy Mini Kit (Qiagen, Hilden,
Germany). The quality of RNA was assessed with
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA,
USA). All samples with an RNA integrity number (RIN)
greater than 9 and an rRNA 28S/18S ratio higher than 1.8
were considered suitable for further analysis. The micro-
array probes were synthesized from 200 ng of total RNA
and labelled with fluorochromes Cy3 and Cy5 using Low
Input Quick Amp Labeling Kit (Agilent Technologies,
Santa Clara, CA, USA), according to the manufacturer’s
instructions. Technical replicates of each sample were
used for hybridisation control (dye-swap design), each
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experiments. In each array, RNA extracted from L-OHP-
resistant cells was compared with RNA extracted from
parental cells. Subsequently, all slides were scanned with
Agilent Technologies scanner G2505BUS45102867 and
quantification of microarray images were done with Fea-
ture Extraction software v. 10.5.3 (Agilent Technologies,
Santa Clara, CA, USA).
Microarray analysis
Microarray data analysis was performed in R statistical
programming language [68]. Background and foreground
intensity ratios were computed taking log2 ratios of inten-
sities for red (R) and green (G) fluorescence channels (M
values). No background subtraction was applied due to
the weak correlation between background and foreground
intensity ratios (ρ < 0.08). Within-array normalization was
carried out using Loess regression. Data were further
subjected to between-array normalization by quantile
method. Median M values (log2(R/G) values) for duplicate
spots were computed and used in class comparison ana-
lysis to identify changes in gene expression profiles in-
volved in L-OHP-resistance acquiring process of Colo320
and HT-29 cell lines.
Quantitative real-time PCR (qRT-PCR)
The expression levels of the genes selected by micro-
array were re-evaluated by qRT-PCR using Light Cycler
480 (Roche Applied Science, Penzberg, Germany) with
primers (1 μM) and Universal Probe Library (UPL)
probes (0.2 μM). In silico design of UPL probes and
primers were obtained from Roche Applied Science Soft-
ware as follow: PTPRO: F-ctatggagacatcactgtggaga, R-tcct
gcatctcgtcagca (UPL#6); KRT18: F-tgatgacaccaatatcacacga,
R-ctgggcttgtaggcctttta (UPL#63); NDRG1: F-gggtgcagaagg
gactagg, R-tgctcctggacatcaaactct (UPL#22); ID1:F-gctgctc
tacgacatgaacg, R-ctcaccttgcggttctgg (UPL#22); WIF1: F-cc
agggagacctctgttcaa, R-ttgggttcatggcaggtt (UPL#76); AVEN
F-ggtggtccaagaggaagaagt, R-gaaatcatgctgtccaacca (UPL#22);
TGFB1 F-gcagcacgtggagctgta, R-cagccggttgctgaggta (UPL#
72); MDK: F-ctcttagcggatgcagcac, R- ccgcccttcttcaccttatc
(UPL#63); CYR61: F-aagaaacccggatttgtgag, R-gctgcatttcttgc
ccttt (UPL#66); 18 s rRNA: F-gcaattattccccatgaacg, R-ggg
acttaatcaacgcacgc (UPL#48). Each reaction was performed
in 5 μl of 1:10 (v/v) dilution of the first cDNA strand syn-
thesized with First Strand cDNA Synthesis Kit (Roche Ap-
plied Science, Germany) from 1 μg of the total RNA. The
cDNA was then amplified with the Light Cycler Taqman
Master Kit (Roche Applied Science, Germany) in a final
volume of 20 μl. Thermal cycle conditions included 10 mi-
nutes at 95°C for enzyme activation followed by 40 cycles
of 15 seconds at 95°C, 20 seconds at 55°C and 1 second at
72°C for the amplification step and 30 seconds at 40°C for
the cooling step. The fluorescent signals of UPL probeswere used to calculate the cycle thresholds. The target
genes were normalized to 18S rRNA housekeeping gene
and quantified using the comparative threshold cycle (2-
ddct) method described by Livak and Schmittgen [69].
Statistical analysis
Statistical processing of the cytotoxicity, CA and qRT-PCR
results were done using GraphPad Prism software program,
version 5.0 (San Diego, CA, USA). Statistical comparison
between groups were made by one-way Anova and
Bonferroni posttest and by unpaired two-tailed t test for
qRT-PCR data (p < 0.05). For the microarray experiment,
the correlation between background and foreground inten-
sity ratios (M values) was assessed in R using Spearman’s
rank correlation test. Differentially expressed (DE) genes
between resistant and parental cell lines were selected with
Limma package/R by fitting a linear model to the expres-
sion data for each gene and using empirical Bayes methods
to moderate the standard errors across genes [70]. A gene
was considered differentially expressed if M value was lower
than −0.58 or greater than 0.58 (at least 1.5 -fold down- or
up-regulation in resistant versus parental cells) and p value
adjusted for multiple testing < 0.05 (Benjamini and
Hochberg method). Pearson correlation between micro-
array and qRT-PCR results were performed in GraphPad
Prism software program, version 5.0 (San Diego, CA, USA).
Functional analysis
Functional profiling was performed using Ingenuity Path-
way Analysis (IPA) software (Ingenuity Systems, Redwood
City, California) [64]. Accession numbers of DE genes as-
sociated with M values were uploaded into the software.
Using information stored in the Ingenuity Knowledge Base
(IKB), genes were mapped to genetic networks, molecular
functions and canonical pathways. The significance of the
association between the genes and the molecular functions
and the canonical pathways was determined by Fischer’s
exact test (p < 0.05). IPA Upstream Regulator Analysis was
used to identify key molecules (upstream regulators)
which can affect the expression of their target genes and
can regulate each other. To predict the activation state of
the upstream regulators (“activated” or “inhibited”), a z-
score was computed for each of them. The terms “acti-
vated” or “inhibited” does not necessary mean that the
regulator is literally activated respectively inhibited. An
“activated” upstream regulator indicates a molecule
expected to be more active in the resistant cell lines than
in the parental ones. A p-value less than 0.01 and a z-
score greater than 2 (prediction state: “activated”) or
smaller than −2 (prediction state: “inhibited”) were consid-
ered significant.
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